• Injection • For weight loss/ obesity • Use according to NICE guidance
The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place.
Prescribe by brand (Saxenda ®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes
Rybelsus is a tablet for once-daily oral use but has special administration directions:
It must be taken on an empty stomach at any time of the day.
Patients are required to wait at least 30 minutes before eating/drinking or taking other oral medicinal products. Waiting less than 30 minutes decreases absorption.
It should be swallowed whole with a sip of water (up to half a glass of water equivalent to 120 ml).
Semaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on Prescribing; manufacturer advises to record the brand name and batch number after each administration.
The use of semaglutide for this indication is restricted to prescribing by commissioned clinics in secondary care by a consultant led specialistmultidisciplinary Tier 3 weight management service with a commercial agreement in place.
Prescribe by brand (Wegovy®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes.
06.01.02.03
Meglitinides
06.01.02.03
SGL2 inhibitors
06.01.02.03
Other
06.01.02.03
Thiazolidinediones
....
Non Formulary Items
Key
Restricted Drug
Unlicensed
Link to adult BNF
Link to children's BNF
Link to SPCs
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
ICB
Low carbon footprint
Medium carbon footprint
High carbon footprint
Status
Description
Medicines which are suitable for initiation and maintenance prescribing by primary and secondary care clinicians. These medicines should be initiated and prescribed within their licensed indications
Amber Specialist Initiation: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing when appropriate. This may be supported by a RICaD, annotated within the formulary entry.
Amber Shared Care: Initiation and maintenance of prescribing by Specialists and transfer to Primary Care prescribing, in accordance with an ESCA, annotated within the formulary entry.
Amber Specialist Recommendation: Initiation and maintenance of prescribing in Primary Care following recommendation from a specialist.
Medicines for initiation and maintenance prescribing by Specialists (hospital or GPs with Special Interest) only
Positive NICE TA and /or awaiting local clarification on place in therapy; Please contact your Medicines Optimisation team for more information.
Non-formulary Medicines which APC/Trust DTC has actively reviewed and do not recommend for use.
